

# Guidelines to Authors

## Scope

*The Indian Journal of Chest Diseases & Allied Sciences (IJCDAS)* is a biomedical quarterly Journal with international circulation. It considers manuscripts covering clinical and experimental work related with all aspects of chest diseases and allied sciences.

It publishes original articles (with original research), review articles (both narrative and evidence-based), radiology forum, case reports, short/brief research communication, clinical images of interest, book reviews and letter to the editor.

Papers that make a significant contribution to the existing state of knowledge in a particular field be considered for publication.

The IJCDAS discourages duplication of data already published in other journals, with certain changes/addition are made.

## The Editorial Policy

All manuscripts submitted to the IJCDAS and considered suitable for processing are subject to peer review process. Authors need to certify in the covering letter that this manuscript has not been submitted to any other journal simultaneously.

All manuscripts are screened initially at the editorial office for suitability for consideration for publication. Those found suitable are sent to 2-3 reviewers, including a statistical expert based on the need. The journal follows the double blind peer review process.

After peer review process, manuscripts considered suitable for publication are suitably edited before publication.

The processes of submission of manuscript, peer review, communication of final decision and sending proofs are done through online system.

## TYPE OF MANUSCRIPTS

### 1. Original Articles

The approximate length of article should preferably be 2500-3500 words (excluding Abstract and References). Original research articles should include a structured abstract (of 250 words maximum) under four subheadings: (i) Background, (ii) Methods, (iii) Results, and (iv) Conclusions, followed by 3-6 key words arranged alphabetically. The main article should include the sections in following order: Introduction, Material and Methods, Results, Discussion, Conclusion(s), Acknowledgment (if any), Conflicts of Interest and References. The permission from Ethics Committee/ Institutional Review Board (IRB) is mandatory for all studies on human subjects and animals and this should be mentioned in the Material and Methods section. Registration of clinical trials is mandatory and registration number/CTR number should be mentioned.

The methods used for statistical analysis of the data should be specified.

### 2. Reviews

Narrative review articles written by scientist(s)/ expert(s) working in the particular area and who has/have published quality original research, will be considered. The article could be 5000-6000 words (excluding Abstract and References) with not more than 100 references (recent and relevant) and an unstructured abstract of about 250 words. Tables and Figures could be included as per requirement. Copyright permission should be obtained from the copyright holder in advance, if a published Table/Figure is reproduced in part or whole.

### 3. Systematic Reviews (Including Meta-analysis)

The articles under this section will be critical appraisal of different studies on important topics of clinical/public health significance to obtain an unbiased quantitative estimate of the overall effect of an intervention or variable for a defined outcome. The focus could be on cause, diagnosis, prognosis, therapy, prevention, etc. These would be thoroughly researched articles giving comprehensive and balanced perspective. There should be a structured abstract. Systematic reviews could be about 2500-3000 words with minimum number of Tables/Figures. These will be published subject to peer review.

### 6. Short/Brief Communication

Original research manuscripts containing well defined study design and sample size but limited parameters analysed may be submitted as Short Papers. These would be about 2000 words and contain an unstructured abstract with a combined Results & Discussion section. A research correspondence would be either a preliminary/pilot study or a post-implicative report with no abstract. Submissions with preliminary investigative data with limited methodology and sample size but having important clinical implications may be submitted as a Short Note containing a 200 words unstructured abstract. Both Correspondence and Short Note would be of around 1000-1500 words containing either a Table and/or a Figure.

### 7. Radiology Forum

Rare and educative cases may be presented under this section. A maximum of two authors are allowed per clinical image submission of whom, one should be a faculty associated with the case. A concise write up without reference or running title, of around 125-150 words may be submitted, containing details of the place (department/institute) and period (month/year) of patient presentation, diagnosis, treatment and follow up (along with the duration of follow up). Clear and well resolved images (up to 3-4 or as panels; JPEG/TIFF format with at least 300 dpi resolution) may be submitted with the write up.

## SUBMISSION OF MANUSCRIPT

Manuscripts must be submitted online: [ijcdas@yahoo.co.in](mailto:ijcdas@yahoo.co.in).

The IJCDAS does not charge for submission and processing of the manuscript.

All manuscripts submitted for publication to the IJCDAS should include the following: (1) **First page**; (2) **Article file**; (3) **Tables & Figures**; (4) **A scanned copy of ethical clearance certificate**; (5) **Undertaking by authors**. Details are given below:

### 1. First Page

This should include a Covering letter, Title page and include: (i) Type of manuscript: original article/ review/ correspondence/ perspective/ clinical image/ letter to editor; (ii) Title; (iii) name(s) of author(s) with highest degree; (iv) name(s) of the Department(s); (v) designations (academic position) of authors in the department; (vi) Short title; (vii) one of the authors should be identified as the corresponding author of the paper, who would be responsible for the contents of the paper as for communication with the Publication office with all above mentioned details; (viii) Number of Tables; (ix) Number of Figures; (x) Source of financial support in the form of grants; (xi) Registration number in case of Clinical Trials.

### 2. Article File

Manuscripts must be submitted online: [ijcdas@yahoo.co.in](mailto:ijcdas@yahoo.co.in). processing or publication of articles. Manuscripts should be presented in as concise form as possible, typewritten neatly. Pages should be numbered consecutively and the contents arranged in the following order:

#### Title

Title of the article should be short, continuous (broken or hyphenated titles are *not* acceptable) and yet sufficiently descriptive and informative so as to be useful in indexing and information retrieval.

#### Title Page

Title page should include name(s) of author(s) with highest degree, departmental affiliations, designation (position) in the department

**Short running title not exceeding 5-6 words must also be provided.**

#### Abstract and Key words:

A set of suitable Key words (3-6 in number) arranged alphabetically should be provided.

All original manuscripts should have a structured abstract (of about 250 words) with subheadings of *Background*, *Methods*, *Results*, and *Conclusions*. Abstract should be brief and indicate the scope and significant results of the paper. It should only highlight the principal findings and conclusions so that it can be used by abstracting services without modification. Conclusions and recommendations not found in the text of the articles should not be included in the Abstract.

#### Introduction

It should briefly review the current state of knowledge strictly concerning the topic of the paper. No mention should be made of the results obtained or conclusions drawn. Review of the literature should be restricted to reasons for undertaking the present study and provide only the most essential background. The objective of the study should be written clearly with adequate justification.

#### Material and Methods

The nomenclature, the source of material and equipment used, with the manufacturer's details in parenthesis, should be clearly mentioned. The procedures adopted should be explicitly stated to enable other workers to reproduce the results, if necessary. New methods may be described in sufficient detail indicating their limitations. Established methods can be just mentioned with authentic references and significant deviations, if any given, with reasons for adopting them. While reporting experiments on human subjects and animals, it should be clearly mentioned that procedures followed are in accordance with the ethical standards laid down by the national bodies or organizations of the particular country. The drugs and chemicals used should be precisely identified, including generic name(s), dosage(s) and route(s) of administration.

**Study design:** Selection of the observational or experimental participants (patients or laboratory animals, including controls, whether randomly or consecutively) and basis of sample size calculation should be mentioned clearly, including eligibility and exclusion criteria and a description of the source population. Period (with month and year) and place of the study should be clearly stated.

Contributors may consult the following Guidelines for specific study designs:

Sr. No.	Type of study	Source
1.	Randomized controlled trials (RCTs)	CONSORT- <a href="http://www.consort-statement.org">http://www.consort-statement.org</a>
2.	Systematic reviews & meta-analysis	PRISMA guidelines- <a href="http://www.prisma-statement.org">http://www.prisma-statement.org</a>
3.	Observational studies in epidemiology	STROBE - <a href="http://www.strobe-statement.org/">http://www.strobe-statement.org/</a>
4.	Meta-analysis of observational studies in epidemiology	MOOSE <a href="http://statswrite.eu/pdf/MOOSE%20Statement.pdf">http://statswrite.eu/pdf/MOOSE%20Statement.pdf</a>
5.	Studies on diagnostic accuracy	STARD - <a href="http://www.stard-statement.org">http://www.stard-statement.org</a>

**Studies based on clinical trials:** All clinical trials should be registered in a Primary Clinical Trial Registry and the Registration number to be given under Material and Methods. Articles presenting with results of randomized clinical trials should provide information on all major study elements, including the protocol, assignment of interventions (methods of randomization, concealment of allocation to treatment groups), and the method of masking (blinding), based on the CONSORT Statement (<http://www.consort-statement.org/>). It should be clearly stated that study protocol was approved by the institutional ethics committee. The statistical analysis done and statistical significance of the findings should be mentioned.

## Results

The data should be arranged in unified and coherent sequence so that the report develops clearly and logically. Data presented in Tables and Figures should not be repeated in the text. Only important observations need to be emphasised or summarised. The same data should not be presented both in tabular and graphic forms.

## Discussion

The discussion should deal with the interpretation of results without repeating information already presented under Results. It should relate new findings to the known ones and include logical deductions. It should also mention any weaknesses/limitations/lacunae of the study.

The conclusions can be linked with the goals of the study but unqualified statements and conclusions not completely supported by the data should be avoided. All hypotheses should, if warranted, clearly be identified as such; recommendations may be included as part of the Discussion, only when considered absolutely necessary and relevant. This section should preferably end with a concluding remark.

## Acknowledgment

Acknowledgment should be brief and made for specific scientific/technical assistance and financial support only and not for providing routine departmental facilities and encouragement or for help in the preparation of the manuscripts (including typing or secretarial assistance).

## Financial support and Sponsorship

Acknowledgment should be made for funding support and /or sponsorship received from national or international funding agencies.

## Conflicts of Interest

A conflict of interest exists if authors or their institutions have financial or personal relationships with other people or organizations that could inappropriately influence (bias) their actions. A conflict can be actual or potential, and full disclosure to the Editor is absolute requirement. All submissions must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest.

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. If there are no conflicts of interest, authors should state so.

## References

The total number of References should normally be restricted to a maximum of 30 for Original Research Articles.

References should be typed on a separate page after the text and these should be numbered consecutively in the order in which they are first mentioned in the text. Identify references in text, tables, and legends by Arabic numerals in parentheses. References cited only in tables or figure legends should be numbered in accordance with the sequence established by the first identification in the text of the particular table or figure. The titles of journals should be abbreviated according to the style used in *Index Medicus*. Consult the *List of Journals Indexed in Index Medicus PMC*, published annually as a separate publication by the library and as a list in the January issue of *PUBs*. The list can also be obtained through the library's web site (<http://www.nlm.nih.gov>). Unpublished work should not be cited in references, but may be cited fully parenthetically within the text. List all the authors when there are six or fewer; but when there are seven or more, list the first six, then 'et al'. Examples of correct form of references are given here:

### Articles in Journals

#### 1. Standard Journal Article

Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. *N Engl J Med* 2002; 347: 284-7.

More than six authors: List the first six authors followed by *et al*.

Rose ME, Huerbin MB, Melick J, Marion DW, Palmer AM, Schiding JK, *et al*. Regulation of interstitial excitatory amino acid concentrations after cortical contusion injury. *Brain Res* 2002; 935: 40-6.

#### 2. Article Published Electronically Ahead of the Print Version

Yu WM, Hawley TS, Hawley RG, Qu CK. Immortalization of yolk sac-derived precursor cells. *Blood* 2002 Nov15; 100(10): 3828-31. Epub 2002 July 5.

#### 3. Volume with Supplement

Geraud G, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short-and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; 42 (Suppl. 2): S93-9.

#### 4. Issue with Supplement

Glaser TA. Integrating clinical trial data into clinical practice. *Neurology* 2002; 58 (12 Suppl. 7): S6-12.

#### 5. Type of Article Indicated as Needed

Tor M, Turker H. International approaches to the prescription of long-term oxygen therapy [letter]. *Eur Respir J* 2002; 20: 242.

Lofwall MR, Strain EC, Brooner RK, Kindbom KA, Bigelow GE. Characteristics of older methadone maintenance (MM) patients [abstract]. *Drug Alcohol Depend* 2002; 66 (Suppl. 1): S105.

6. *Volume with Part*

Abend SM, Kulish N. The psychoanalytic method from an epistemological viewpoint. *Int J Psychoanal* 2002; 83 (Pt 2): 491-5.

7. *Issue with Part*

Ahrar K, Madoff DC, Gupta S, Wallace MJ, Price RE, Wright KC. Development of a large animal model for lung tumours. *J Vasc Interv Radiol* 2002; 13(9 Pt 1): 923-8.

8. *Issue with No Volume*

Banit DM, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop* 2002; (401): 230-8.

9. *No Volume or Issue*

Outreach: bringing HIV-positive individuals into care. *HRSA Careaction* 2002 Jun: 1-6.

10. *Pagination in Roman Numerals*

Chadwick R, Schuklenk U. The politics of ethical consensus finding. *Bioethics* 2002; 16: iii-v.

11. *Organization as Author*

Diabetes Prevention Program Research Group. Hypertension, insulin, and pro insulin in participants with impaired glucose tolerance. *Hypertension* 2002;40:679-86.

12. *Both personal authors and an organization as author* (This example does not conform to NISO standards).

Vallancien G, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; 169: 2257-61.

13. *No Author Given*

21st century heart solution may have a sting in the tail. *BMJ* 2002; 325: 184.

14. *Article Containing Retraction*

Feifel D, Moutier CY, Perry W. Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone. *J Clin Psychiatry* 2002;63(2):169. Retraction of: Feifel D, Moutier CY, Perry W. *J Clin Psychiatry* 2000; 61: 909-11.

15. *Article Retracted*

Feifel D, Moutier CY, Perry W. Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone. *J Clin Psychiatry* 2000;61:909-11. Retraction in: Feifel D, Moutier CY, Perry W. *J Clin Psychiatry* 2002; 63: 169.

16. *Article Republished with Corrections*

Mansharamani M, Chilton BS. The reproductive importance of P-type ATPases. *Mol Cell Endocrinol* 2002;188:22-5. Corrected and republished from: *Mol Cell Endocrinol* 2001;183:123-6.

17. *Article with Published Erratum*

Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. *Clin Ther* 2000; 22: 1151-68; discussion 1149-50. Erratum in : *Clin Ther* 2001;23(2):309.

18. *Article not in English* (Note: NLM translates the title into English, encloses the translation in square brackets, and adds an abbreviated language designator.)

Ellingsen AE, Wilhelmsen I. *Sykdomsangst blant medisinstudentene*. *Tidsskr Nor Laegeforen* 2002;122:785-7.

**Personal Communication**

Name of the person and date of communication should be cited in parentheses in the text. For scientific articles, authors should obtain written permission and confirmation of accuracy from the source of a personal communication.

**Unpublished Material**

19. *In press* (Note: NLM prefers "forthcoming" because not all items will be printed.)

Tian D, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in *Arabidopsis*. *Proc Natl Acad Sci USA*. In press 2002.

**Books and Other Monographs**20. *Chapter in a Book*

Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumours. In: Vogelstein B, Kinzler KW, editors *The Genetic Basis of Human Cancer*. New York: McGraw-Hill;2002:pp93-113.

21. *Conference Paper*

Christensen S, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors *Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming*; 2002 Apr 3-5; Kinsdale Ireland. Berlin: Springer; 2002:pp182-91.

22. *Personal Author(s)*

Murray PR, Rosenthal KS, Kobayashi GS, Pfaffler MA. *Medical Microbiology*; 4th edition. St. Louis: Mosby; 2002.

23. *Editor(s), Compiler(s) as Author*

Gilstrap LC (3rd), Cunningham FG, VanDorsten JP, editors. *Operative Obstetrics*; 2nd edition. New York:McGraw-Hill; 2002.

24. *Author(s) and Editor(s)*

Breedlove GK, Schorfheide AM. *Adolescent Pregnancy*. 2nd edition Wiczorek RR, editor. White Plains (NY): March of Dimes Education Services; 2001.

25. *Organization(s) as Author*

Royal Adelaide Hospital; University of Adelaide, Department of Clinical Nursing. *Compendium of Nursing Research and Practice Development, 1999-2000*. Adelaide (Australia): Adelaide University; 2001.

26. *Conference Proceedings*

Harnden P, Joffe JK, Jones WG, editors. Germ cell tumours V. *Proceedings of the 5th Germ Cell Tumour Conference*; 2001 Sep 13-15; Leeds, UK. New York: Springer; 2002.

27. *Scientific or Technical Report*

Issued by funding/sponsoring agency:

Yen GG (Oklahoma State University, School of Electrical and Computer Engineering, Stillwater, OK). Health monitoring on vibration signatures. Final report. Arlington(VA): Air Force Office of Scientific Research (US), Air Force Research Laboratory; 2002 Feb. Report No.: AFRLSRBLTR020123. Contract No.: F496209810049.

Issued by performing agency:

Russell ML, Goth-Goldstein R, Apte MG, Fisk WJ. Method for measuring the size distribution of airborne Rhinovirus. Berkeley (CA): Lawrence Berkeley National Laboratory, Environmental Energy Technologies Division; 2002 Jan. Report No.: LBNL49574. Contract No.: DEAC0376SF00098. Sponsored by the Department of Energy.

28. *Dissertation*

Borkowski MM. Infant sleep and feeding: a telephone survey of Hispanic Americans [dissertation]. Mount Pleasant (MI): Central Michigan University; 2002.

29. *Patent*

Pegedas AC, inventor; Ancel Surgical R& D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1.

**Other Published Material**30. *Newspaper Article*

Tynan T. Medical improvements lower homicide rate: study sees drop in assault rate. *The Washington Post*. 2002 Aug 12; Sect. A: 2 (col. 4).

31. *Audiovisual Material*

Chason KW, Sallustio S. Hospital preparedness for bioterrorism [videocassette]. Secaucus (NJ): Network for Continuing Medical Education; 2002.

32. *Legal Material*

Public law:

Veterans Hearing Loss Compensation Act of 2002, Pub.L.No. 107-9, 115 Stat. 11 (May 24, 2001).

Unenacted bill: Healthy Children Learn Act, S. 1012, 107th Cong., 1st Sess. (2001).

Code of Federal Regulations:

Cardiopulmonary Bypass Intracardiac Suction Control, 21 C.F.R. Sect. 870.4430 (2002).

Hearing:

Arsenic in Drinking Water: An Update on the Science, Benefits and Cost: Hearing Before the Subcomm. on Environment, Technology and Standards of the HouseComm. on Science, 107th Cong., 1st Sess. (Oct. 4, 2001).

33. *Map*

Pratt B, Flick, P, Vynne C, cartographers. Biodiversity hotspots [map]. Washington: Conservation International; 2000.

34. *Dictionary and Similar References*

Dorland's *Illustrated Medical Dictionary*. 29th ed. Philadelphia: W.B. Saunders; 2000. Filamin; p. 675.

**Electronic Material**35. *CD-ROM*

Anderson SC, Poulsen KB. *Anderson's Electronic Atlas of Hematology* [CD-ROM]. Philadelphia: Lippincott Williams & Wilkins; 2002.

36. *Journal Article on the Internet*

Aboud S. Quality improvement initiative in nursing homes: the ANA acts in an advisory role. *Am J Nurs* [serial on the Internet]. 2002 Jun [cited 2002 Aug 12];102(6) : [about 3 p.]. Available from URL: <http://www.nursingworld.org/AJN/2002/june/Wawatch.htm>. Accessed on January 25, 2014.

37. *Monograph on the Internet*

Foley KM, Gelband H, editors. Improving palliative care for cancer [monograph on the Internet]. Washington: National Academy Press; 2001 [cited 2002 Jul 9]. Available from URL: <http://www.nap.edu/books/0309074029/html/>. Accessed on January 25, 2014.

38. *Homepage/Website*

Cancer-Pain.org [homepage on the Internet]. New York: Association of Cancer Online Resources, Inc.; c2000-01 [updated 2002 May 16; cited 2002 Jul 9]. Available from URL: <http://www.cancer-pain.org/>. Accessed on January 25, 2014.

39. *Part of a homepage/Website*

American Medical Association [homepage on the Internet]. Chicago: The Association; c1995-2002 [updated 2001 Aug 23; cited 2002 Aug 12]. AMA Office of Group Practice Liaison; [about 2 screens]. Available from URL: <http://www.ama-assn.org/ama/pub/category1736.html>. Accessed on January 25, 2014.

40. *Database on the Internet*

Open database:

Who's Certified [database on the Internet]. Evanston (IL): The American Board of Medical Specialists. c2000-[cited 2001 Mar 8]. Available from URL: <http://www.abms.org/newsearch.asp>. Accessed on January 25, 2014.

Closed database:

Jablonski S. Online Multiple Congenital Anomaly/Mental Retardation (MCA/MR) Syndromes [database on the Internet]. Bethesda (MD): National Library of Medicine (US). c1999 [updated 2001 Nov 20; cited 2002 Aug 12]. Available from URL: [http://www.nlm.nih.gov/mesh/jablonski/syndrome\\_title.html](http://www.nlm.nih.gov/mesh/jablonski/syndrome_title.html). Accessed on January 25, 2014.

41. *Part of a database on the Internet*

MeSH Browser [database on the Internet]. Bethesda (MD): National Library of Medicine (US); 2002 - [cited 2003 Jun 10]. Meta-analysis; unique ID: D015201; [about 3 p.]. Available from URL: <http://www.nlm.nih.gov/mesh/MBrowser.html> Files updated weekly. Accessed on January 25, 2014.

MeSH Browser [database on the Internet]

Bethesda(MD): National Library of Medicine (US); 2002 - [cited2003 Jun 10]. Meta-analysis; unique ID: D015201; [about3 p.]. Available from URL: <http://www.nlm.nih.gov/mesh/MBrowser.html> Files updated weekly. Accessed on January 25, 2014.

**Correctness of the reference list is the entire responsibility of the author (s).**

## Figures and Tables

**Figures.** Photographs are required (10 cm × 8 cm, 300 dpi in JPEG or TIFF); good black and white contrast is essential for good reproduction. All illustrations must be numbered and cited in the text. Legends should be provided for each illustration, listed on a separate page. Within a multi-panel figure, different parts should be labelled as A, B, C,...etc. on top left corner. Symbols, arrows and letters used in the photomicrographs should be legible and in contrast with the background. All lettering must be done professionally. Freehand or typed lettering is not acceptable. **Colour illustrations must be paid by the authors. Please ask rates/charges from the Publication Office of the IJCDAS.**

**Tables.** Each table should be typed double-spaced on a separate sheet. These should have an underlined title followed by a legend, if any. Explanatory matter should be in a footnote, not in the title. The approximate position of each table in the text should be indicated in the margin of the manuscript.

**Page Proofs and Reprints.** A galley proof will be sent to the corresponding author online that should be returned within four days. Corrections should be limited to printer's errors only and no substantial additions/deletions should be made. No change in the names of authors (by way of additions and/or deletions) is permissible at the proof stage.

*Papers which have been accepted/ published become the property of the Indian Journal of Chest Diseases and Allied Sciences and permission to re-publish them must be obtained from the Editor.*

## Abbreviations

Only standard abbreviations are to be used. The abbreviations should conform to the International System of Units (SI), throughout the text, Tables and Figures. Generic names of the drugs should be used. If proprietary brands are used in research brand name, name of manufacturer and country should be given in parentheses after the generic name at the first place of use.

## ETHICAL CLEARANCE CERTIFICATE

All studies conducted on patients / volunteers/ Human biological material/animals should submit a scanned copy of Ethical Clearance Certificate.

## Standard abbreviations to be used in IJCDAS

The abbreviations should be used in the text, tables and illustrations without a full stop.

Molar (mole/litre)	M	hour(s)	h
milli molar (m mole/litre)	mM	minute(s)	min
Micromolar (mole/litre)	μM	second(s)	sec
mole (quantity of substance)	mol	week(s)	wk
normal	N	year(s)	yr
metre	m	Probability	
centimetre	cm	(statistical significance)	P
millimetre	mm	counts per minute	cpm
micrometre	μm	intramuscular	im
nanometre	nm	intraperitoneal	ip
picometre	pm	intravenous	iv
mg/ 100 mL	mg/dL	subcutaneous	sc
litre	L	oral	po
millilitre	mL	anti meridiem (before noon)	am
microlitre	μL	post meridiem (after noon)	pm
gram	g	volume	vol
milligram	mg	weight	wt
kilogram	kg		

### ***Online Manuscript Submission Check List***

*The Indian Journal of Chest Diseases and Allied Sciences [ijcdas.yahoo.co.in]*

- Covering letter including copy-right release
- Manuscript of the article on A-4 size paper
- Name and address of author responsible for correspondence about the manuscript, including highest degree and affiliations of each author [not less than Assistant Professor].
- Abstract (up to 250 words) along with 3-6 key words
- Running title (5-6 words)
- All illustrations (10 cm × 8 cm 300 dpi in JPEG), appropriately labelled and each illustration is cited within the text.
- Check all references for accuracy and completeness. Put references in proper format in numerical order, making sure each is cited in the text.
- Scanned copy of Undertaking duly signed by all authors should be submitted as single file (sequence of authors should be maintained as per title page).

**The Indian Journal of Chest Diseases and Allied Sciences**  
*Publication Division*  
*V.P. Chest Institute*  
*University of Delhi*  
*Delhi - 110 007*

**UNDERTAKING BY AUTHORS**

We, the undersigned, give an undertaking to the following effect with regard to our article entitled

---



---



---

submitted for publication in the *Indian Journal of Chest Diseases and Allied Sciences*:

1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal;
2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by use here; and
3. We also agree to the authorship of the article in following sequence:

	Author's Name(s) (in sequence)	Signature of Author(s)
1.	_____	_____
2.	_____	_____
3.	_____	_____
4.	_____	_____
5.	_____	_____
6.	_____	_____
7.	_____	_____
8.	_____	_____

**IMPORTANT**

1. All the authors are required to sign this form independently in the sequence given above.
2. Each author should have generated at least a part of the intellectual content of the paper.
3. Each author should be able to defend publicly in the scientific community, that intellectual content of the paper for which he/she can take responsibility.
4. No addition/deletion/or any change in the sequence of the authorship will be permissible at a later stage